Literature DB >> 1433516

Posttranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins through a heterologous RNA binding site.

D McDonald1, T J Hope, T G Parslow.   

Abstract

The human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins induce cytoplasmic expression of incompletely spliced viral mRNAs by binding to these mRNAs in the nucleus. Each protein binds a specific cis-acting element in its target RNAs. Both proteins also associated with nucleoli, but the significance of this association is uncertain because mutations that inactivate nucleolar localization signals in Rev or Rex also prevent RNA binding. Here we demonstrate that Rev and Rex can function when tethered to a heterologous RNA binding site by a bacteriophage protein. Under these conditions, cytoplasmic accumulation of unspliced RNA occurs without the viral response elements, mutations in the RNA binding domain of Rev do not inhibit function, and nucleolar localization can be shown to be unnecessary for the biological response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1433516      PMCID: PMC240426     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency.

Authors:  M H Malim; B R Cullen
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

2.  Trans-activation by HIV-1 Tat via a heterologous RNA binding protein.

Authors:  M J Selby; B M Peterlin
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

3.  Circular dichroism studies of the HIV-1 Rev protein and its specific RNA binding site.

Authors:  T J Daly; J R Rusche; T E Maione; A D Frankel
Journal:  Biochemistry       Date:  1990-10-23       Impact factor: 3.162

4.  Functional analysis of human T-cell leukemia virus type I rex-response element: direct RNA binding of Rex protein correlates with in vivo activity.

Authors:  C Ballaun; G K Farrington; M Dobrovnik; J Rusche; J Hauber; E Böhnlein
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev.

Authors:  J Kjems; A D Frankel; P A Sharp
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

6.  Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element.

Authors:  J Kjems; M Brown; D D Chang; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

7.  Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.

Authors:  C Southgate; M L Zapp; M R Green
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

8.  The three-dimensional structure of the bacterial virus MS2.

Authors:  K Valegård; L Liljas; K Fridborg; T Unge
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

9.  Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif.

Authors:  T J Hope; X J Huang; D McDonald; T G Parslow
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

10.  Definition of the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex protein activation domain by functional exchange.

Authors:  I Weichselbraun; G K Farrington; J R Rusche; E Böhnlein; J Hauber
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more
  39 in total

1.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Anti-Rex aptamers as mimics of the Rex-binding element.

Authors:  S Baskerville; M Zapp; A D Ellington
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Formation of Tap/NXT1 heterodimers activates Tap-dependent nuclear mRNA export by enhancing recruitment to nuclear pore complexes.

Authors:  Heather L Wiegand; Glen A Coburn; Yan Zeng; Yibin Kang; Hal P Bogerd; Bryan R Cullen
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

4.  Using viral species specificity to define a critical protein/RNA interaction surface.

Authors:  G A Coburn; H L Wiegand; Y Kang; D N Ho; M M Georgiadis; B R Cullen
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

5.  Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence.

Authors:  M Dobbelstein; J Roth; W T Kimberly; A J Levine; T Shenk
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

6.  The UL69 transactivator protein of human cytomegalovirus interacts with DEXD/H-Box RNA helicase UAP56 to promote cytoplasmic accumulation of unspliced RNA.

Authors:  Peter Lischka; Zsolt Toth; Marco Thomas; Regina Mueller; Thomas Stamminger
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

7.  Exon junction complexes mediate the enhancing effect of splicing on mRNA expression.

Authors:  Heather L Wiegand; Shihua Lu; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

8.  Resistance to RevM10 inhibition reflects a conformational switch in the HIV-1 Rev response element.

Authors:  Michal Legiewicz; Christopher S Badorrek; Kevin B Turner; Daniele Fabris; Tiffany E Hamm; David Rekosh; Marie-Louise Hammarskjöld; Stuart F J Le Grice
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-05       Impact factor: 11.205

Review 9.  Nuclear localization signals overlap DNA- or RNA-binding domains in nucleic acid-binding proteins.

Authors:  E C LaCasse; Y A Lefebvre
Journal:  Nucleic Acids Res       Date:  1995-05-25       Impact factor: 16.971

10.  Cellular protein modulates effects of human immunodeficiency virus type 1 Rev.

Authors:  Y Luo; H Yu; B M Peterlin
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.